No connection

Search Results

MENS vs PRQR

MENS
Jyong Biotech Ltd.
BEARISH
Price
$2.79
Market Cap
$212.1M
Sector
Healthcare
AI Confidence
95%
PRQR
ProQR Therapeutics N.V.
BEARISH
Price
$1.99
Market Cap
$209.7M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
MENS
--
PRQR
--
Forward P/E
MENS
--
PRQR
-4.23
P/B Ratio
MENS
-8.91
PRQR
3.63
P/S Ratio
MENS
--
PRQR
12.83
EV/EBITDA
MENS
-121.13
PRQR
-3.13

Profitability

Gross Margin
MENS
0.0%
PRQR
100.0%
Operating Margin
MENS
0.0%
PRQR
-192.9%
Profit Margin
MENS
0.0%
PRQR
-258.05%
ROE
MENS
--
PRQR
-61.17%
ROA
MENS
-5.44%
PRQR
-19.35%

Growth

Revenue Growth
MENS
--
PRQR
6.1%
Earnings Growth
MENS
--
PRQR
--

Financial Health

Debt/Equity
MENS
--
PRQR
0.32
Current Ratio
MENS
0.62
PRQR
3.09
Quick Ratio
MENS
0.62
PRQR
3.0

Dividends

Dividend Yield
MENS
--
PRQR
--
Payout Ratio
MENS
0.0%
PRQR
0.0%

AI Verdict

MENS BEARISH

MENS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a critical lack of fundamental value. The company reports a negative Price-to-Book ratio of -8.91, indicating negative shareholders' equity, and a Current Ratio of 0.62, signaling an immediate liquidity crisis. With zero reported revenue and a catastrophic 95% price decline over the last six months, the stock appears to be in a speculative death spiral. Recent short-term gains are likely volatility-driven 'dead cat bounces' rather than a fundamental recovery.

Strengths
Recent short-term price recovery (+40.9% in 1 month)
Small market cap allows for high volatility spikes
Operates in the high-growth Healthcare/Biotech sector
Risks
Negative book value indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.62)
Complete absence of revenue and profit margins
PRQR BEARISH

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe fundamental weakness across all measured financial dimensions. While the company maintains a strong liquidity position with a Current Ratio of 3.09 and low Debt/Equity (0.32), it suffers from extreme operational inefficiency with a profit margin of -258.05%. There is a stark divergence between the objective financial data and the 'Strong Buy' analyst consensus, suggesting the valuation is based on speculative pipeline catalysts rather than current fiscal performance. The technical trend is entirely bearish (0/100), further compounding the negative outlook.

Strengths
Strong short-term liquidity (Current Ratio 3.09)
Low leverage (Debt/Equity 0.32)
Strong analyst conviction with a target price of $8.88
Risks
Critical fundamental failure (Piotroski F-Score 0/9)
Extreme negative profitability (Profit Margin -258.05%)
High valuation relative to sales (P/S 12.83)

Compare Another Pair

MENS vs PRQR: Head-to-Head Comparison

This page compares Jyong Biotech Ltd. (MENS) and ProQR Therapeutics N.V. (PRQR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile